Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Atea Pharmaceuticals, Inc.

AVIR Nasdaq Pharmaceutical Preparations Financials FY2018โ€“FY2025

Last close ยท Oct 23, 2026

$4.04

0.2%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$158M
Free cash flow Cash from operations minus capital spending.
โ€”
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$323M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$2.08 EPS (TTM)

What Atea Pharmaceuticals, Inc. does

No business description yet.

Legal name
Atea Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 5, 2026
Accession ยท CIK
0001193125-26-094159
0001593899

Revenue and margins

Atea Pharmaceuticals, Inc. had โ€” of revenue in fiscal 2025.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โ€” in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Atea Pharmaceuticals, Inc. returned $25.5M to shareholders in fiscal 2025. The diluted share count fell 3.3%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Atea Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $764M$647M$578M$455M$302M
Current ratio 13.6x35.8x18.2x24.9x7.8x
Quick ratio 13.6x35.8x18.2x24.9x7.8x
Total assets $773M$667M$595M$465M$315M
Total liabilities $62.8M$26.1M$39.8M$25.8M$39.8M
Shareholders' equity $710M$641M$555M$439M$275M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ“ โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โ€” โœ“ โœ“ โœ• โœ• โœ• โœ•
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ• โœ• โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โ€” โœ• โœ“ โœ“ โœ• โœ“ โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ“ โœ• โœ• โœ“
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โ€” โœ“ โ€” โ€” โ€” โ€”
F-score โ€” / 3โ€” / 4โ€” / 64 / 7โ€” / 6โ€” / 6โ€” / 6โ€” / 6
Accruals ratio โ€”โˆ’5.5%โˆ’69.5%25.4%0.7%โˆ’8.0%โˆ’6.2%โˆ’6.7%
Altman Z'' โ€”โˆ’27.245.6519.3830.4517.8818.783.65

8 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue โ€” โ€” $48.6M $351M โ€” โ€” โ€” โ€”
Research and development $6.7M $10.2M $38.0M $167M $81.9M $114M $144M $148M
Operating income โˆ’$9.5M โˆ’$14.6M โˆ’$11.0M $138M โˆ’$131M โˆ’$164M โˆ’$193M โˆ’$181M
Pretax income โ€” โˆ’$14.0M โˆ’$10.9M $139M โˆ’$119M โˆ’$135M โˆ’$167M โˆ’$165M
Income tax โ€” โ€” โ€” $17.4M โˆ’$3.6M $1.0M $0.9M โˆ’$6.2M
Net income โˆ’$9.1M โˆ’$14.0M โˆ’$10.9M $121M โˆ’$116M โˆ’$136M โˆ’$168M โˆ’$158M
Diluted EPS โˆ’$0.90 โˆ’$1.39 โˆ’$0.51 $1.37 โˆ’$1.39 โˆ’$1.63 โˆ’$2.00 โˆ’$1.94
Diluted shares 0.01B 0.01B 0.02B 0.09B 0.08B 0.08B 0.08B 0.08B
Cash flow
Cash from operations โˆ’$7.9M โˆ’$12.8M $297M โˆ’$87.0M โˆ’$121M โˆ’$85.4M โˆ’$135M โˆ’$132M
Capital expenditure $0.0M $0.0M $0.0M $0.0M $1.9M โ€” โ€” โ€”
Free cash flow โˆ’$7.9M โˆ’$12.8M $297M โˆ’$87.0M โˆ’$123M โ€” โ€” โ€”
Depreciation and amortization $0.0M $0.0M $0.0M $0.0M $0.3M $0.4M $0.4M $0.4M
Stock-based compensation $0.4M $0.6M $7.5M $39.6M $46.7M $49.4M $51.8M $20.7M
Share buybacks โ€” โ€” โ€” โ€” โ€” โ€” $0.0M $25.5M
Dividends and buybacks โ€” โ€” โ€” โ€” โ€” โ€” $0.0M $25.5M
Balance sheet
Cash and short-term investments $34.5M $21.7M $850M $764M $647M $578M $455M $302M
Current assets โ€” $21.9M $863M $772M $661M $590M $462M $311M
Current liabilities โ€” $2.4M $316M $56.9M $18.5M $32.4M $18.6M $39.8M
Property and equipment, net โ€” $0.0M $0.0M $0.0M $1.7M $1.3M $0.9M $0.5M
Total assets โ€” $22.1M $864M $773M $667M $595M $465M $315M
Total liabilities โ€” $2.5M $316M $62.8M $26.1M $39.8M $25.8M $39.8M
Shareholders' equity โˆ’$36.2M โˆ’$49.6M $548M $710M $641M $555M $439M $275M
Margins
Operating margin โ€” โ€” โˆ’22.7% 39.4% โ€” โ€” โ€” โ€”
EBITDA margin โ€” โ€” โˆ’22.6% 39.4% โ€” โ€” โ€” โ€”
Net margin โ€” โ€” โˆ’22.5% 34.5% โ€” โ€” โ€” โ€”
FCF margin โ€” โ€” 610.1% โˆ’24.8% โ€” โ€” โ€” โ€”
Returns
Return on capital employed โ€” โˆ’74.4% โˆ’2.0% 19.3% โˆ’20.2% โˆ’29.2% โˆ’43.3% โˆ’65.7%
Return on equity โ€” โ€” โˆ’4.4% 19.3% โˆ’17.2% โˆ’22.7% โˆ’33.9% โˆ’44.3%
Return on assets โ€” โˆ’63.6% โˆ’2.5% 14.8% โˆ’16.1% โˆ’21.6% โˆ’31.8% โˆ’40.6%
Return on tangible equity โ€” โ€” โˆ’2.0% 17.1% โˆ’18.1% โˆ’24.5% โˆ’38.4% โˆ’57.5%
Growth
Revenue growth โ€” โ€” โ€” 622.5% โ€” โ€” โ€” โ€”
Net income growth โ€” โ€” โ€” โ€” โˆ’195.6% โ€” โ€” โ€”
EPS growth โ€” โ€” โ€” โ€” โˆ’201.5% โ€” โ€” โ€”
FCF growth โ€” โ€” โ€” โˆ’129.3% โ€” โ€” โ€” โ€”
Share count change โ€” 0.5% 114.0% 308.7% โˆ’5.7% 0.2% 1.0% โˆ’3.3%
Financial health
Current ratio โ€” 9.0x 2.7x 13.6x 35.8x 18.2x 24.9x 7.8x
Quick ratio โ€” 9.0x 2.7x 13.6x 35.8x 18.2x 24.9x 7.8x
Capital allocation
Capex / revenue โ€” โ€” 0.1% 0.0% โ€” โ€” โ€” โ€”
Stock comp / revenue โ€” โ€” 15.3% 11.3% โ€” โ€” โ€” โ€”
Quality scores
Piotroski F-score โ€” โ€” โ€” 4.0 โ€” โ€” โ€” โ€”
Altman Z'' โ€” โˆ’27.2 5.6 19.4 30.4 17.9 18.8 3.7
Accruals ratio โ€” โˆ’5.5% โˆ’69.5% 25.4% 0.7% โˆ’8.0% โˆ’6.2% โˆ’6.7%

Source: SEC EDGAR XBRL filings (CIK 0001593899). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open